Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Anand

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 22, 2002
Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?P Murali Doraiswamy, K Ranga Rama Krishnan, Ravi Anand, et al.
Case Reports in Rheumatology|May 11, 2013
Unilateral RS3PE in a Patient of Seronegative Rheumatoid ArthritisAnkur Nandan Varshney, Nilesh Kumar, Ashutosh Tiwari, et al.
Biological Psychiatry|August 14, 2003
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trialSteven G Potkin, Larry Alphs, Chuanchieh Hsu, et al.
Transfusion Medicine Reviews|October 17, 2017
A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy VolunteersShodeinde A Coker, Zbigniew M Szczepiorkowski, Alan H Siegel, et al.
The American Journal of Psychiatry|February 2, 2002
A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomographySteven G Potkin, Gustavo Alva, Kirsten Fleming, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 22, 2014
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's diseaseRupam Borgohain, Jozsef Szasz, Paolo Stanzione, et al.
JAMA Neurology|December 13, 2016
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical TrialAnthony H V Schapira, Susan H Fox, Robert A Hauser, et al.
Nature Communications|May 25, 2019
Evidence for fungi and gold redox interaction under Earth surface conditionsTsing Bohu, Ravi Anand, Ryan Noble, et al.
Schizophrenia Bulletin|January 6, 2005
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patientsLarry Alphs, Ravi Anand, M Zahur Islam, et al.
Alzheimer Disease and Associated Disorders|June 19, 2002
Barriers to drug discovery and development for Alzheimer diseaseHoward M Fillit, Alan W O'Connell, William M Brown, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 22, 2002
Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?P Murali Doraiswamy, K Ranga Rama Krishnan, Ravi Anand, et al.
Case Reports in Rheumatology|May 11, 2013
Unilateral RS3PE in a Patient of Seronegative Rheumatoid ArthritisAnkur Nandan Varshney, Nilesh Kumar, Ashutosh Tiwari, et al.
Biological Psychiatry|August 14, 2003
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trialSteven G Potkin, Larry Alphs, Chuanchieh Hsu, et al.
Transfusion Medicine Reviews|October 17, 2017
A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy VolunteersShodeinde A Coker, Zbigniew M Szczepiorkowski, Alan H Siegel, et al.
The American Journal of Psychiatry|February 2, 2002
A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomographySteven G Potkin, Gustavo Alva, Kirsten Fleming, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 22, 2014
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's diseaseRupam Borgohain, Jozsef Szasz, Paolo Stanzione, et al.
JAMA Neurology|December 13, 2016
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical TrialAnthony H V Schapira, Susan H Fox, Robert A Hauser, et al.
Nature Communications|May 25, 2019
Evidence for fungi and gold redox interaction under Earth surface conditionsTsing Bohu, Ravi Anand, Ryan Noble, et al.
Schizophrenia Bulletin|January 6, 2005
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patientsLarry Alphs, Ravi Anand, M Zahur Islam, et al.
Alzheimer Disease and Associated Disorders|June 19, 2002
Barriers to drug discovery and development for Alzheimer diseaseHoward M Fillit, Alan W O'Connell, William M Brown, et al.
Pageof 5